Compare Inovio Pharmaceuticals Inc (INO) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while NRG Energy Inc trades at $132.04 (market cap $27.55B). The key difference: NRG Energy Inc is far larger — about 308.6× Inovio Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.46% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NRG | |
|---|---|---|
Market Cap | $89.27M | $27.55B |
Sector | Health | Utilities |
52-Week High | $2.87 | $184.03 |
52-Week Low | $1.05 | $120.65 |
Enterprise Value | $60.28M | $51.38B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
NRG Energy trades at $131.02, up 1.48% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth to $30.71B but thin net margins of 0.74%. Analyst consensus remains bullish with a $196.33 price target, representing 50% upside potential from current levels. Recent news highlights expanding generation capacity and data center deals as growth catalysts.
The outlook balances strong analyst support against elevated valuation multiples and technical weakness. Key opportunities include power demand growth and strategic positioning, while risks involve margin pressure and debt levels exceeding 56% of assets. The upcoming Q2 2026 earnings report on August 4 will be critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
